Does levosimendan act as a Ca 2+ sensitizer or PDE 3 inhibitor?: Commentary on Orstavik et al ., Br J Pharmacol 171: 5169–5181
Linked Article This article is a Commentary on Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, Levy FO, Skomedal T, Osnes J‐B, and Qvigstad E (2014). PDE3‐inhibition by levosimendan is sufficient to account for its inotropic effect in failing human heart . Br J Pharmacol 171: 5169–5181. doi: 10.1...
Saved in:
| Published in | British journal of pharmacology Vol. 172; no. 18; pp. 4594 - 4596 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
01.09.2015
|
| Online Access | Get full text |
Cover
Loading…
| Summary: | Linked Article
This article is a Commentary on Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, Levy FO, Skomedal T, Osnes J‐B, and Qvigstad E (2014). PDE3‐inhibition by levosimendan is sufficient to account for its inotropic effect in failing human heart . Br J Pharmacol 171: 5169–5181. doi:
10.1111/bph.12647 |
|---|---|
| ISSN: | 0007-1188 1476-5381 |
| DOI: | 10.1111/bph.12649 |